About the clinical trial
In January 2023, we started the Single-R trial at ITM, in which we are investigating modified (shortened) administration schedules for the rabies vaccine. More than 120 healthy volunteers between 18 and 60 years old were included in the trial and divided into three groups:
Group 1: One intramuscular (into the muscle) administration of 1ml vaccine on day 1
Group 2: Four intradermal (into the skin) administrations of 0.1ml vaccine on day 1
Group 3 (control group): standard schedule of two intramuscular administrations of 1ml at 7-day interval
The end of the trial is expected in the first half of 2024.
For scientific background on the trial, check the EU Clinical Trials Register, the database in which clinical trials must be officially registered.
Contact us at email@example.com.
Share this trial on